Knockdown and knockout of TRAF4 dramatically reduced both the stability of HER2 receptor and the activation of HER2 downstream signaling pathways, improving sensitivity of breast cancer cells and PDX-derived organoids to Trastuzumab treatment. This evidence concerns the gene TRAF4 and breast carcinoma.